Never Run Out Of Buyers To Sell To.

7 Primus Biosciences, Inc. is redefining precision oncology through innovative science and breakthrough technologies. Our flagship asset, 7PB-100, is a first-in-class, orally available BAK activator that drives selective tumor cell death while sparing healthy tissue—delivering impressive preclinical results and a game-changing patient profile. Utilizing our proprietary CombYSelect platform, we engineer versatile bispecific antibodies and bispecific antibody-drug conjugates (ADCs) that precisely target novel cancer antigens, enabling the delivery of powerful payloads—including BAK activators…
Annual Revenue$1M to $5M
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.